Innovating Works
HCO-10-2014
HCO-10-2014: ERA NET rare disease research implementing IRDiRC objectives
Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 15-04-2014.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.

 

Scope: Proposals should coordinate national and regional programmes for research on rare diseases by preparing and implementing a transnational call with EU co-funding, resulting in grants to third parties, with a view to implement IRDiRC[2] objectives and identified priorities. This call should aim at furthering the understanding of disease mecha... ver más

Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.

 

Scope: Proposals should coordinate national and regional programmes for research on rare diseases by preparing and implementing a transnational call with EU co-funding, resulting in grants to third parties, with a view to implement IRDiRC[2] objectives and identified priorities. This call should aim at furthering the understanding of disease mechanisms and natural history of rare diseases with the objective to develop new diagnostic tools and treatments. Selected proposals should adhere to the policies and guidelines of IRDiRC.

 

Proposals should be complementary with other funding programmes and activities on European and international level.

 

Proposals should demonstrate the expected impact on national and transnational programmes and IRDiRC objectives as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

 

Proposals should also aim at implementing other joint activities including training and additional joint calls without EU co-funding. 

 

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

In line with the Union’s strategy for international cooperation in research and innovation[3], the project will contribute to reaching the overall goals of IRDiRC; Deepened and extended coordination of national and transnational research in the field of rare diseases resulting in a substantial contribution to the overall goals of IRDiRC; Streamlined national/regional and international practices in organising research funding; Increased interoperability of national research programmes; Increased sharing of data and knowledge; Increased networking of infrastructures and databases.  

Type of action: ERA-NET Co-fund

[1] www.irdirc.org

[2] The IRDiRC policies and guidelines document is available on: http://www.irdirc.org/?page_id=12

[3] COM(2012)497


Cross-cutting Priorities:International cooperationERA-NET


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals. Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.
2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
3. Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme
3.2 Guide to the submission and evaluation process
4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.
5. Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
ERANET Cofund:
Specific provisions and funding r...
Please read carefully all provisions below before the preparation of your application.
1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.
2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
3. Evaluation
3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme
3.2 Guide to the submission and evaluation process
4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.
5. Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
ERANET Cofund:
Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Standard evaluation form
Annotated Model Grant Agreement
 
7. Additional provisions:
Horizon 2020 budget flexibility
Classified information
8. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-HCO-2014-2015 ERA NET rare disease research implementing IRDiRC objectives Scope:Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare dis...
Sin info.
SC1-HCO-01-2018-2019-2020 Actions in support of the International Consortium for Personalised Medicine
en consorcio:
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-HCO-03-2020 Bridging the divide in health research and innovation – boosting return on investment
en consorcio: Specific Challenge:The Innovation Union Scoreboard reveals significant disparities in terms of research and innovation performance among the...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-HCO-17-2020 Coordinating and supporting research on the human microbiome in Europe and beyond
en consorcio: Specific Challenge:Integration and application of metagenomics data from the human microbiome has shown large potential for personalised med...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-HCO-07-2020 ERA-NET to support the Joint Programming Initiative on Antimicrobial resistance (JPIAMR)
en consorcio: Specific Challenge:Antimicrobial resistance (AMR) is a serious challenge that has reached alarming levels in the EU and globally. There is a...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-HCO-19-2020 Reliable and accessible information on cell and gene-based therapies
en consorcio: Specific Challenge:Cell and gene-based therapies have the potential to treat many debilitating diseases and conditions. However, the pace of...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de